[
    [
        {
            "time": "",
            "original_text": "【东吴医药】华兰生物2019年一季报点评：血液制品行业回暖，拉动一季度业绩增速25%超预期",
            "features": {
                "keywords": [
                    "华兰生物",
                    "血液制品",
                    "行业回暖",
                    "业绩增速",
                    "超预期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【东吴医药】华兰生物2019年一季报点评：血液制品行业回暖，拉动一季度业绩增速25%超预期",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "反弹一触即发？利空被澄清，五一节前“业绩雷”将爆完，4月聪明钱“爆买”这些股！",
            "features": {
                "keywords": [
                    "反弹",
                    "利空澄清",
                    "业绩雷",
                    "聪明钱",
                    "爆买"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "反弹一触即发？利空被澄清，五一节前“业绩雷”将爆完，4月聪明钱“爆买”这些股！",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医疗保健：继续推荐3+2主线 荐2股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "3+2主线",
                    "荐股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗保健"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医疗保健：继续推荐3+2主线 荐2股",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "医疗保健：震荡做底后将挑战前高 荐6股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "震荡做底",
                    "挑战前高",
                    "荐股"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗保健"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医疗保健：震荡做底后将挑战前高 荐6股",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医疗保健：关注创新题材及业绩高速增长个股机会 荐14股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "创新题材",
                    "业绩增长",
                    "个股机会",
                    "荐股"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗保健"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医疗保健：关注创新题材及业绩高速增长个股机会 荐14股",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "跑输各自业绩比较基准 兴银国都九泰三产品问题曝光",
            "features": {
                "keywords": [
                    "跑输",
                    "业绩比较基准",
                    "产品问题",
                    "曝光"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "跑输各自业绩比较基准 兴银国都九泰三产品问题曝光",
                "Correlation": 3,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【国盛医药张金洋团队】详解2019Q1机构医药持仓，继续推荐医药流通",
            "features": {
                "keywords": [
                    "国盛医药",
                    "机构持仓",
                    "医药流通",
                    "推荐"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国盛医药张金洋团队】详解2019Q1机构医药持仓，继续推荐医药流通",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "【国信医药|年报暨一季报点评】博雅生物：符合预期，期待调浆获批",
            "features": {
                "keywords": [
                    "博雅生物",
                    "年报",
                    "一季报",
                    "调浆获批",
                    "符合预期"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国信医药|年报暨一季报点评】博雅生物：符合预期，期待调浆获批",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "华兰生物:血制品供需格局趋于稳定,助公司稳健增长",
            "features": {
                "keywords": [
                    "华兰生物",
                    "血制品",
                    "供需格局",
                    "稳定",
                    "稳健增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华兰生物:血制品供需格局趋于稳定,助公司稳健增长",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "华兰生物:业绩增长略超预期,血制品增长有望超预期",
            "features": {
                "keywords": [
                    "华兰生物",
                    "业绩增长",
                    "略超预期",
                    "血制品",
                    "有望超预期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华兰生物:业绩增长略超预期,血制品增长有望超预期",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]